In this section
@article{Pinato:2019:10.1186/s40425-019-0775-x,
author = {Pinato, DJ and Gramenitskaya, D and Altmann, DM and Boyton, RJ and Mullish, BH and Marchesi, JR and Bower, M},
doi = {10.1186/s40425-019-0775-x},
journal = {Journal for ImmunoTherapy of Cancer},
title = {Antibiotic therapy and outcome from immune-checkpoint inhibitors},
url = {http://dx.doi.org/10.1186/s40425-019-0775-x},
volume = {7},
year = {2019}
}
TY - JOUR
AB - Sensitivity to immune checkpoint inhibitor (ICPI) therapy is governed by a complex interplay of tumor and host-related determinants. Epidemiological studies have highlighted that exposure to antibiotic therapy influences the probability of response to ICPI and predict for shorter patient survival across malignancies. Whilst a number of studies have reproducibly documented the detrimental effect of broad-spectrum antibiotics, the immune-biologic mechanisms underlying the association with outcome are poorly understood. Perturbation of the gut microbiota, an increasingly well-characterized factor capable of influencing ICPI-mediated immune reconstitution, has been indicated as a putative mechanism to explain the adverse effects attributed to antibiotic exposure in the context of ICPI therapy. Prospective studies are required to validate antibiotic-mediated gut perturbations as a mechanism of ICPI refractoriness and guide the development of strategies to overcome this barrier to an effective delivery of anti-cancer immunotherapy.
AU - Pinato,DJ
AU - Gramenitskaya,D
AU - Altmann,DM
AU - Boyton,RJ
AU - Mullish,BH
AU - Marchesi,JR
AU - Bower,M
DO - 10.1186/s40425-019-0775-x
PY - 2019///
SN - 2051-1426
TI - Antibiotic therapy and outcome from immune-checkpoint inhibitors
T2 - Journal for ImmunoTherapy of Cancer
UR - http://dx.doi.org/10.1186/s40425-019-0775-x
UR - http://hdl.handle.net/10044/1/73861
VL - 7
ER -
For any enquiries about the Microbiome Network at Imperial, please contact: